AKT1 and esophageal squamous cell carcinoma: The results demonstrated by Zhu et al. (2020) indicated that Omipalisib suppressed the activation of both PI3K/AKT/mTOR and ERK signaling in all ESCC cell lines, indicating that this inhibitor can suppress MAPK feedback activation.